Therefore, we feel it prudent, in the iterative spirit of drug development, that the structure of existing C2 correctors be interrogated to identify the precise pharmacophore responsible for BKCa versus CFTR regulation, in order to design more selective compounds for CF. Here, CFTR is linked to cystic fibrosis.